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LimitationsCardiac resynchronization therapy (CRT) has become amainstay of heart failure treatment. Since heart failure
is a disease primarily affecting older patients it is important to evaluate the performance of CRT in this
population.
Elderly has been suggested as a subgroup less likely to beneﬁt from CRT. This is an important issue that should
be clariﬁed, because most patients with heart failure are old.
The present review discusses the available data concerning cardiac resynchronization therapy in the elderly,
focusing on efﬁcacy, indication, safety, and impact of co-morbidities.Hospitais da Universidade de
rtugal. Tel.: +351 239400656;
nio).
Ltd. All rights reserved.
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Heart failure (HF) is the fastest growing cardiovascular disease and
it carries a poor prognosis, even with optimal pharmacotherapy [1].
Additionally, HF is a condition that dramatically impairs the quality of
life, particularly in older patients and mostly when it is associated
with typical age-associated comorbidities.
The prevalence of HF rises sharply with age, so the prevalence in
70- to 80-year-old people is between 10 and 20% [2]. Probable reasons
are the age-related changes in ventricular function, the cumulative
effects of chronic risk factors (particularly arterial hypertension), in
addition to the enhanced therapy for acute myocardial infarction and
acute HF [3].
HF is a condition that dramatically impairs the quality of life,
particularly in older patients and mostly when it is associated with
typical age-associated comorbidities. In patients older than 65, at least
20% of hospital admissions are due to HF [4].
Several randomized controlled trials have shown improved out-
comes with CRT in appropriately selected patients with systolic HF
and evidence of dyssynchrony [5,6]. Potential mechanisms of beneﬁt
include improved contractile function and reverse ventricular
remodeling. The usual inclusion criteria include NYHA classes III to
IV HF despite optimal medical therapy, left ventricular ejection
fraction (LVEF) b35%, and QRS duration of N120 ms [2].
Despite the encouraging results from CRT in recent trials, patients'
responses to CRT vary signiﬁcantly and up to 30% of patients receivingCRT are “non-responders” [7]. Concerns about costs have encouraged
the search for patient's subgroups more likely to beneﬁt from CRT. Of
note, elderly has been suggested as a subgroup of patients less likely
to beneﬁt from CRT. This is an important issue that should be clariﬁed,
because most patients with HF are old.
Although HF is a disease of the elderly, data on the efﬁcacy and
safety of CRT in this population are scarce. Older patients are poorly
represented in almost all large-scale CRT trials and little data exists on
the effects of CRT in the elderly [8].
In this review, we tried to summarize the current knowledge
regarding the use of CRT devices in elderly HF patients based on
subgroup analyses of prospective randomized trials, and based on
published cohort studies.
1.1. CRT efﬁcacy and indications in the elderly
Heart failure patients in clinical practice are almost a decade older
than the trial participants [1].
To date, it remains unclear, whether the favorable results of CRT
therapy are generalizable to elderly patients, because few old patients
have been included in clinical trials as summarized in Table 1.
Additionally, randomized trials have not speciﬁcally addressed the
beneﬁt of CRT in elderly patients.
In twomajor CRT trials (CARE-HF and COMPANION), the mean age
was about 65 years and the beneﬁt from CRT was similar in patients
above and below the mean age [6,9].
The COMPANION trial randomized 1520 patients (mean age 67)
with advanced heart failure to receive CRT alone or CRT with
prophylactic ICD back-up (CRT-D) in a 1:2:2 ratio [9]. At a mean
follow-up of 12 months, there was a signiﬁcant reduction in the
incidence of the primary composite end point of all-cause mortalityly: A realistic option for an increasing population?,
Table 1
Important prospective CRT trials with subgroup analysis by age.
Study Year Age Number of patients Results
COMPANION [9] 2004 65±11 1520 Reduction of all-cause mortality or hospitalization
CARE-HF [6] 2005 67 (60–73) 813 Reduction of mortality or hospitalization
Improvement in NYHA functional class, quality of life and ejection fraction
MIRACLE [10] 63.9±10.7 453 Improvement in NYHA functional class, 6-minute walk test, quality of life and ejection fraction
MIRACLE-ICD [11] 2003 66.6±11.3 369 Improvement in NYHA functional class and quality of life
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receiving CRT compared to the arm receiving pharmacological
therapy alone. On a subgroup analysis the primary end point did
not vary with age, with similar beneﬁt of CRT for patients below and
above the age of 65 years [12].
Another landmark CRT trial, the CARE-HF study also included
many elderly patients. That trial randomly assigned 813 patients
(mean age 67) with NYHA class III or IV HF to optimized medical
therapy alone or plus CRT. At a mean follow-up of 29 months, CRT
signiﬁcantly improved the symptoms and the quality of life and
reduced the total mortality [6]. Again, a subgroup analysis demon-
strated a similar beneﬁt for patients below and above the age of
66.4 years.
A recently published subgroup analysis by age of the MIRACLE and
MIRACLE-ICD trials showed that elderly patients who receive CRT
have comparable improvement in NYHA class and LVEF as younger
patients [13].
Equivalent beneﬁts of CRT were also noted in observational studies
comparing elderly with younger patients [14,15]. Bleeker et al. [14]
showed after a relatively short follow-up of 6-months a similar clinical
and echocardiographic (improvement in the LV ejection fraction and
extent of LV reverse remodeling) responses in patients≥70 years of age
(mean age 76) compared to patients b70 years of age (mean age 59).
Moreover, survival at 1-year after implantationwas comparable in both
groups [14]. More recently, Delnoy et al. [15] also demonstrated a
similar clinical and echocardiographic beneﬁt of CRT in patients
aged N75 years in comparison to younger patients.
Unfortunately, elderly heart failure patients N75 years, octogenarians
or patients with more severe comorbidities have been largely underrep-
resented or excluded in CRT trials.
Recently, the efﬁcacy of CRT in octogenarians has been evaluated
in the Insync/Insync ICD Italian registry. In that study, which included
1181 patients (85 of whom were ≥80 years old) CRT demonstrated
similar efﬁcacy in patients aged ≥80 years and in those under 80, in
terms of clinical and functional parameters, reverse remodeling and
even cardiac mortality [3].
In conclusion, based on the results of all these clinical studies,
there seems to be no reasonable doubt that the full age range of
patients with advanced HF and appropriate indication can beneﬁt
from CRT. Therefore, in elderly patients without major comorbidities,
the data support the use of CRT devices for standard indication
according to published guidelines.
1.2. Complications of CRT in the elderly
Overall, transvenous biventricular pacemaker implantation is a safe,
well-tolerated, procedure with a high rate of successful implantation in
the ﬁrst attempt [16].
Cohort studies have demonstrated low perioperative mortality
rates for CRT in geriatric patients, including octogenarians [3]. In fact,
in the Insync/Insync ICD Italian registry, no major complication
occurred during the implant procedure, and device-related complica-
tions observed during the follow-up were relatively rare. LV leads
dislodged occurred in 4.4% of patients aged b80 years and in 2.4%
aged ≥80 years (P=NS) and 1.8% pocket erosions were reported in
the b80 years group [3].Please cite this article as: António N, et al, Cardiac resynchronization the
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trials, there was no evidence of increased adverse events after CRT
implantation in the elderly [13]. However, this study suffers the
limitations of a post-hoc analysis. In fact, to date, no prospective,
randomized trial has speciﬁcally addressed the safety of CRT in the elderly.
1.3. Impact of comorbidities
Comorbidities such as atrial ﬁbrillation, peripheral vascular
disease, diabetes, pulmonary disease, depression, anemia and renal
dysfunction complicate HF care and are prevalent in one form or
another for the majority of elderly patients scheduled for CRT [17].
The question of whether older patients with multiple comorbid-
ities will beneﬁt in terms of survival and quality of life from
implantation of costly devices is important. However, despite the
fact that elderly patients scheduled for CRT in “the real world” clinical
practice usually present several co-morbidities, this type of patients
has clearly been underrepresented in prospective CRT trials.
Renal dysfunction is a common comorbidity in HF and is
individually associated with poorer outcomes [18]. However, it has
been demonstrated that renal impairment does not prevent the
positive response to CRT, even in elderly patients [19]. Actually,
previous studies have indicated that CRT can be a renal-protective
strategy in HF and that the improvement in renal function can be
another mechanism to explain the beneﬁcial effects of CRT [20–22].
Diabetes and chronic HF commonly coexist [23]. In addition,
diabetes is a powerful independent predictor of morbidity and
mortality among patients with HF [24]. Regarding the impact of
diabetes on CRT effectiveness, previous studies have demonstrated
that this frequent comorbidity is not a predictor of poor response
[19,25]. In fact, diabetic HF patients treated with CRT seem to have a
very favorable functional and survival outcome, which is comparable
to non-diabetic patients [26].
Theprevalence of atrialﬁbrillation (AF) in patientswithHFvarieswith
severity, ranging from5% inpatientswithNYHAfunctional class I to40% in
patients with NYHA class IV and markedly increases with age [27].
A recent metanalysis of prospective cohort studies comparing CRT
in patients with AF and sinus rhythm, concluded that patients with AF
show signiﬁcant improvement after CRT with similar or slightly
greater improvements in left ventricular ejection fraction than
patients in sinus rhythm [28].
All the available data indicate that even elderly patients with co-
morbidities, but with a good life expectancy, could beneﬁt from CRT.
Nevertheless, comorbidities should certainly be considered when
determining whether an elderly patient will beneﬁt from a HF device
or not and could also inﬂuence the decision ofwhichdevice to implant—
aCRT-Pprimarily to improvequalityof life or aCRT-D to improvequality
of life and to prolong survival? In selected elderly patients with severe
HF symptoms and frequent hospitalizations, but severe comorbidities,
CRTwithout ICDback-upmaybea good choice to improvequality of life,
irrespective of impact on mortality.
1.4. CRT plus ICD versus CRT alone
Once an indication for CRT has been conﬁrmed the choice of the
most appropriate device (CRT-P or CRT-D) needs to be made. Inrapy in the elderly: A realistic option for an increasing population?,
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criteria for ICD implantation. In fact, combination devices account for
more than 80% of CRT implants [29].
Biventricular pacing alone without an ICD backup decreases
mortality [6]. However, in the COMPANION trial, CRT plus ICD showed
a trend toward lower all-cause mortality compared to CRT alone [12].
Moreover, the mortality beneﬁt in COMPANION began immediately in
the CRT plus ICD group compared to eight months with CRT alone [9].
A similar delayed beneﬁt was seen with CRT alone in CARE-HF [6]. Of
note, a recent meta-analysis of randomized controlled trials con-
ﬁrmed that CRT predominantly reduces mortality due to worsening
HF, not affecting sudden cardiac death [30]. These results suggest that
ICD prevents sudden death from the beginning, while the mortality
beneﬁt of CRT requires time for reverse ventricular remodeling.
Importantly, in elderly patients which frequently have several
comorbidities, the choice of the HF device has to consider not only the
potential beneﬁt of the therapy and, the life expectancy but also the
cost-effectiveness related to the device. A beneﬁt-risk evaluation
should always be conducted and the choice between a CRT or CRT plus
ICD must be discussed for each individual elderly patient.
2. Conclusion
Available data from randomized trials as well as from cohort
studies support the conclusion that CRT is effective in the full age
range of patients with advanced HF. Thus, in elderly patients without
major comorbidities, data support the use of CRT-P and CRT-D devices
for standard indication according to published guidelines. For patients
whose functional status and life expectancy are limited predomi-
nantly by chronic noncardiac conditions, the relative risks and
beneﬁts of CRT-P or CRT-D devices must be weighted and discussed
for each patient.
Cost-effectiveness of CRT has not been evaluated in large cohorts
of elderly HF patients. Whether the cost-beneﬁt ratio of younger
patient populations can be extrapolated to elderly patient cohorts
with more comorbidities remains to be determined in the future.
Large, multicenter, randomized trials on CRT in the elderly are
warranted to conﬁrm the net beneﬁt of this therapy in this increasing
population.
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